TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01464489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
Study: NCT02208557

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinforcement with Absorbable Mesh
Study: NCT04560673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02208557

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Control CT
Description: At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Control CT
Description: At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Follow Up
Description: The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
Study: NCT04560673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05367414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy massage (diluted tea tree oil)
Description: massage with diluted tea tree oil was applied

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy massage (sweet almond oil)
Description: massage with sweet almond oil was applied
Study: NCT03729804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
Study: NCT04561232

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prone and Upright Locomotor Training
Description: During the movement observation phase, infants will wear a wireless movement sensor at each ankle for two days. Research staff will show the caregivers how to place the sensors in the morning and charge them overnight.~The training protocol for the prone training will consist of: 1) Warm-up. 2) Assisted movement of the arms and legs. 3) Calibration of the infant's arm and leg positions. 4) Self-initiated mobility for up to five minutes.~For upright training, the environment will be arranged to encourage active motor exploration and variability in walking activities.The therapist will assist the child as needed to encourage upright locomotor activities, but only the minimum amount needed to perform the task. Weight assistance will be gradually reduced as postural control and coordination improve.
Study: NCT04671446

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoantibody ELISA
Description: Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
Study: NCT01120704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Maintenance Counseling
Description: Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Maintenance Counseling
Description: Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Maintenance Counseling
Description: Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 \& 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
Study: NCT01916252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide (Revlimid®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide (Revlimid®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan (Busilvex ®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Study: NCT03501303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No touch technique
Description: Veins for CABG is harvested with the no touch technique
Study: NCT04671446

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoantibody ELISA
Description: Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoantibody ELISA
Description: Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.
Study: NCT06607601

Intervention type: DRUG
Intervention: Palbociclib
Description: Treatment information in the electronic health record indicates initiation of palbociclib after metastatic diagnosis

Intervention type: DRUG
Intervention: Letrozole
Description: Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis

Intervention type: DRUG
Intervention: Letrozole
Description: Treatment information in the electronic health record indicates initiation of letrozole after metastatic diagnosis
Study: NCT03501303

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control technique
Description: Veins for CABG is harvested with the Control technique.
Study: NCT00855933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Floss
Description: Experimental Glide® floss with cetylpyridinium chloride (\~13% dry weight CPC)
Study: NCT00937742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato products
Description: Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
Study: NCT00003783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study: NCT04671446

Intervention type: DIAGNOSTIC_TEST
Intervention: Autoantibody ELISA
Description: Serum will be tested for novel autoantibodies against candidate auto-antigens by ELISA, such as those previously identified as of importance (e.g. eosinophil peroxidase, EPX) and also novel candidate proteins specific to eosinophils as identified by FANTOM5 geneset analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Granulocyte Immunofluorescence
Description: The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
Study: NCT00003783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT04671446

Intervention type: DIAGNOSTIC_TEST
Intervention: Granulocyte Immunofluorescence
Description: The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Granulocyte Immunofluorescence
Description: The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.

Intervention type: DIAGNOSTIC_TEST
Intervention: Granulocyte Immunofluorescence
Description: The presence of auto-antibodies in patient serum to inactive and activated neutrophils / eosinophils, with and without post-translational modification, will be examined by indirect immunofluorescence.
Study: NCT01874769

Intervention type: OTHER
Intervention: Blood collection
Description: * 5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~* 10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~* 5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria.
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT01874769

Intervention type: OTHER
Intervention: Skin biopsies
Description: * A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~* During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study: NCT03354611

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Cone Beam Breast CT Scan
Description: * Pre-contrast scan~* Begin contrast injection (and saline chaser)~* Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Dye, Iodinated
Description: 1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of \~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at \~2 ml/s (20 seconds) to maximize dynamic enhancement.
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study: NCT04145466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The high-fat diet will consist of \~40% energy from fat and \~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Description: The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Description: The high-carbohydrate diet will consist of \~20% of energy from fat and \~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of \~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed
Study: NCT01573442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 10.4 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01728402

Intervention type: PROCEDURE
Intervention: blood draw, bone marrow procedure, or tissue biopsy
Study: NCT05110443

Intervention type: OTHER
Group type: OTHER
Intervention: D-WB PET/CT
Description: Instead of the usual procedure of having the injection of the radiotracer in the waiting room and having to wait 60 minutes before being moved to the scanner room for imaging, the study participants will be injected with the radiotracer already laying on the scanner bed and the scan will commence immediately.~Therefore, in this study the patients are still only being scanned once, but we are gathering PET information in a different way.
Study: NCT04175847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC88
Description: Phase I:Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.~Phase IIa indication exploration
Study: NCT03526835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-158
Description: full-length IgG1 bispecific antibody targeting EGFR and LGR5

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + Pembrolizumab
Description: MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + FOLFIRI
Description: MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MCLA-158 + FOLFOX
Description: MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.
Study: NCT01409161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Given IV
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT01409161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: Given PO
Study: NCT03047837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET
Description: Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET
Description: Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
Study: NCT04423029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study: NCT04423029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF6002
Description: Specified dose on specified days
Study: NCT00003783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02213848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
Study: NCT03006991

Intervention type: OTHER
Intervention: therapeutic drug monitoring
Description: dose of methotrexate can be adjusted by therapeutic drug monitoring.
Study: NCT00711854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (TMP-SMX)
Description: TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid (600 mg IV or PO twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (600 mg IV or PO once daily)